Jump to main content
Jump to site search

Issue 7, 2010
Previous Article Next Article

Arene ruthenium complexes as anticancer agents

Author affiliations

Abstract

Neutral or cationic arene ruthenium complexes providing both hydrophilic as well as hydrophobic properties due to the robustness of the rutheniumarene unit hold a high potential for the development of metal-based anticancer drugs. Mononuclear arene ruthenium complexes containing P- or N-donor ligands or N,N-, N,O- or O,O-chelating ligands, dinuclear arene ruthenium systems with adjustable organic linkers, trinuclear arene ruthenium clusters containing an oxo cap, tetranuclear arene ruthenium porphyrin derivatives that are photoactive, as well as hexanuclear ruthenium cages that are either empty or filled with other molecules have been shown to be active against a variety of cancer cells.

Graphical abstract: Arene ruthenium complexes as anticancer agents

Back to tab navigation

Publication details

The article was received on 14 Aug 2009, accepted on 23 Sep 2009 and first published on 23 Oct 2009


Article type: Perspective
DOI: 10.1039/B916860P
Citation: Dalton Trans., 2010,39, 1673-1688
  •   Request permissions

    Arene ruthenium complexes as anticancer agents

    G. Süss-Fink, Dalton Trans., 2010, 39, 1673
    DOI: 10.1039/B916860P

Search articles by author

Spotlight

Advertisements